Kayvon Modjarrad, MD, PHD

Director, EIDB
Walter Reed Army Institute of Research
Silver Spring, MD, United States

Kayvon Modjarrad, MD, PhD is the founding Director of the Emerging Infectious Diseases Branch at the Walter Reed Army Institute of Research and Associate Professor of Medicine at the Uniformed Services University. Dr. Modjarrad leads the U.S. Army's development of a vaccine against COVID-19, co-leads all of WRAIR’s COVID-19 response efforts and serves as a member of Operation Warp Speed. Dr. Modjarrad is also an advisory member of the World Health Organization’s Strategic Advisory Group of Experts Immunization Working Group on COVID-19 Vaccines and Vaccination.
Dr. Modjarrad's team has developed a SARS-CoV-2 vaccine that is based on a nanoparticle platform that will enter a Phase I clinical trial later this year. He previously co-led the US Army’s Zika vaccine program and was assigned to the World Health Organization in 2015 where he supported the execution of Ebola vaccine trials and authored the Roadmap for MERS Coronavirus vaccine development.
Dr. Modjarrad, originally from New Jersey, began his training in biology at Duke University and then went on to obtain his MD, MPH and PhD through the National Institutes of Health-funded, combined degree, Medical Scientist Training Program. In the course of this training, he went to Lusaka, Zambia, in 2003-2004 as a Boren Fellow, where he established a research clinic, implemented a study to evaluate the impact of parasitic infections on HIV, and bolstered local infrastructure in preparation for the U.S. President’s Emergency Plan for AIDS Relief. He then went on to complete his Internship and Residency in Internal Medicine and Fellowship in Infectious Diseases at Yale, Vanderbilt, and the National Institute of Allergy and Infectious Diseases. Dr. Modjarrad has published more than 70 peer-reviewed manuscripts and has served as the principal editor for two textbooks, most recently one on emerging vaccine technologies.

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 212 - Toward a Universal SARS-CoV-2 Vaccine

  Saturday, October 22, 2022
  10:30 AM – 11:45 AM US ET

• 1645 - From Concept Through Clinical Trial of a Broadly Immunogenic Nanoparticle Vaccine Platform

  Saturday, October 22, 2022
  11:20 AM – 11:45 AM US ET